home / stock / alny / alny news

ALNY News and Press, Alnylam Pharmaceuticals Inc. From 09/13/23

Stock Information
Company Name: Alnylam Pharmaceuticals Inc.
Stock Symbol: ALNY
Market: NASDAQ
Website: alnylam.com
Menu
ALNY ALNY Quote ALNY Short ALNY News ALNY Articles ALNY Message Board
Get ALNY Alerts

News, Short Squeeze, Breakout and More Instantly...
ALNY - Alnylam stock trading halted as FDA AdCom meets on amyloidosis drug

2023-09-13 08:25:41 ET More on Alnylam Seeking Alpha’s Quant Rating on Alnylam Pharmaceuticals Historical earnings data for Alnylam Pharmaceuticals Financial information for Alnylam Pharmaceuticals Alnylam Continues To Deliver, But An Upcoming FDA Meet...
ALNY - Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that NASDAQ has halted trading of the Company’s common stock. The U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee is meeting today t...

ALNY - Alnylam amyloidosis drug led to "small" benefits in Phase 3 trial: FDA

2023-09-11 10:15:39 ET More on Alnylam Seeking Alpha’s Quant Rating on Alnylam Pharmaceuticals Historical earnings data for Alnylam Pharmaceuticals Financial information for Alnylam Pharmaceuticals Alnylam Continues To Deliver, But An Upcoming FDA Meet...

ALNY - Alnylam Continues To Deliver, But An Upcoming FDA Meeting Could Create Some Volatility

2023-09-09 08:26:31 ET Summary Alnylam has an upcoming FDA advisory committee meeting on the company's application for Onpattro in ATTR-CM, and I see some risk of a negative committee vote. Onpattro has met or exceeded the efficacy targets established with the FDA, but I expect th...
ALNY - Alnylam succeeds in Phase 2 trial for blood pressure drug

2023-09-07 08:25:18 ET More on Alnylam, Roche, etc. Alnylam: Unlimited Promise Or Unlimited Losses? Alnylam Pharmaceuticals, Inc. 2023 Q2 - Results - Earnings Call Presentation Alnylam Pharmaceuticals, Inc. ( ALNY ) Q2 2023 Earnings Call Transcript Roche:...

ALNY - Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk

- Zilebesiran Met Primary Endpoint Demonstrating Greater than 15 mmHg Reduction of Systolic Blood Pressure at Three Months of Treatment Compared to Placebo at Two Highest Single Doses Evaluated - - Study Met Key Secondary Endpoints Showing Consistent and Sustained Reductions of Systolic B...

ALNY - First Set of Recommendations Advocating for the Holistic Care of People Living with hATTR Amyloidosis Developed by International Panel of Patient Advocates and Healthcare Professionals

New study published in the BMJ Open calls for major shift in the management of hATTR amyloidosis Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the first-ever recommendations for patient- and family-centred holistic care for peop...
ALNY - Alnylam picked for positive catalyst watch at Citi on amyloidosis therapy.

2023-09-05 13:54:34 ET More on Alnylam Seeking Alpha’s Quant Rating on Alnylam Pharmaceuticals Historical earnings data for Alnylam Pharmaceuticals Financial information for Alnylam Pharmaceuticals Alnylam: Unlimited Promise Or Unlimited Losses? ...

ALNY - Pfizer, Moderna And COVID Vaccine Patents: Implications Of Legal Cases

2023-08-30 16:04:07 ET Summary Moderna and Pfizer/BioNTech earned more than $110 billion from their COVID vaccines, with net profit margins of more than 50%. Alnylam, Arbutus and Genevant are suing Moderna, Pfizer, and BioNTech, alleging they infringed on patents for lipid nanopar...

ALNY - Alnylam appealing patent ruling in case against Moderna

2023-08-28 16:16:00 ET More on Alnylam Pharmaceuticals Alnylam: Unlimited Promise Or Unlimited Losses? Alnylam: Zilebesiran Deal With Roche Reveals A Very Long Development Timeline Roche, Alnylam in pact for blood pressure candidate Alnylam to face FDA AdCom ...
Previous 10 Next 10